First-generation EGFR-targeting tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have achieved good efficacy in NSCLC patients with EGFR mutations and extended their PFS. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.